July 1997 in “The Lancet” This abstract reports preliminary data on the antidepressant reboxetine, noted for its different mode of action, discussed at a major psychiatry conference; it provides no new research findings.
May 2024 in “Reactions weekly” 1 citations
,
December 2025 in “Diagnostics” This case study reported a rare occurrence of cicatricial alopecia linked to zolpidem-induced sleep-related amnestic behavior, highlighting the importance of a comprehensive medication history for accurate diagnosis.
April 2010 in “Nature Reviews Urology”
44 citations
,
October 2010 in “BJUI” This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.
10 citations
,
July 2021 in “International Journal of Women’s Dermatology” In this review, the authors detailed various dermatologic adverse events associated with aromatase inhibitors in postmenopausal women and discussed strategies to potentially prevent these events, aiming to minimize interruptions in breast cancer treatment.
17 citations
,
August 2014 in “American Journal of Physiology-gastrointestinal and Liver Physiology” This study found that finasteride significantly improved motor, EEG, and cellular changes in a rat model of thioacetamide-induced hepatic encephalopathy and prevented the development of hepatic coma.
90 citations
,
December 2007 in “Current Oncology” This review discusses management strategies for sexual side effects of aromatase inhibitors in postmenopausal breast cancer patients and reports no original clinical findings.
June 2026 in “The Journal of Sexual Medicine” This study found that psychiatric adverse drug reactions were more frequently reported with finasteride than with dutasteride, but it remains unclear if there is a causal relationship.
August 2013 in “Hospital Pharmacy” This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.
May 2026 in “AAPS PharmSciTech” This study found that PEGylated LUT-Aspasomes significantly improved neuroprotective effects in stressed rats, enhancing spatial memory, reducing depressive-like behavior, and preserving hippocampal architecture better than free luteolin. Additionally, it increased brain delivery and stability, suggesting potential for treating stress-related neurobehavioral disorders.
1 citations
,
February 2022 in “Clinical and Experimental Health Sciences” In this study, dexpanthenol exhibited antiepileptic and antidepressant-like effects in mice without impacting their motor coordination.
5 citations
,
September 2024 in “Maturitas” In this study, an ultra-low dose combination of estradiol and dydrogesterone significantly reduced hot flushes and improved health-related quality of life among a multi-ethnic population of postmenopausal women, with no notable difference in serious adverse events compared to placebo.
1 citations
,
April 2019 in “Clinical Breast Cancer” This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.
November 2024 in “Journal of Family Medicine and Primary Care” This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.
5 citations
,
October 2020 in “Brain Research Bulletin” This study found that etifoxine pretreatment reduced neuroinflammation and improved cognitive function in LPS-induced neuroinflammation in mice, potentially through increased neurosteroid synthesis and reduced apoptosis.
June 2025 in “The Senior Care Pharmacist” This study observed that certain medications, including antipsychotics, non-sedating antidepressants, and finasteride, were associated with a higher risk of inpatient falls among older adults at a Veterans Affairs Medical Center compared to matched controls.
January 2017 in “ScholarWorks - WMU (Western Michigan University)” This case report suggests that Citalopram may cause reversible hair loss in some patients, as evidenced by hair regrowth after discontinuing the drug.
January 2023 in “Bioorganičeskaâ himiâ” This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.
October 2025 in “Journal of the Endocrine Society” This study observed that finasteride, while lowering cholesterol levels, did not decrease the prevalence of clinical cardiovascular events or new ECG abnormalities in men with benign prostatic hyperplasia compared to controls, suggesting a potential disconnect between cholesterol management and cardiovascular risk reduction with this treatment.
April 2018 in “The Journal of Urology” This study found that dutasteride use was associated with a stable decrease in sexual function over four years, with no additional risk based on age or prostate size.
23 citations
,
July 2003 in “Pharmacology, Biochemistry and Behavior” Finasteride blocks progesterone's effect on absence seizures in rats.
3 citations
,
April 2010 in “Clinical Neuropharmacology” In this case report, a 75-year-old man with benign essential blepharospasm and Parkinson disease experienced significant symptom relief from dystonia after starting finasteride, suggesting it may be a potential therapeutic option.
9 citations
,
March 1989 in “The BMJ” Adding diltiazem to a beta blocker can cause dangerously slow heart rates.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
August 2009 in “Australian Prescriber” This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.
This paper provides a comprehensive list of drugs including Ethamolin, Placidyl, Trecator-SC, Zarontin, Peganone, Didronel, and Lodine, detailing their indications, potential interactions, and reported adverse skin reactions, but it presents no new research findings.
January 2024 in “Authorea (Authorea)” This study found that Sudanese epilepsy patients prioritize medication intake despite cosmetic effects from antiepileptic drugs, which may be influenced by cultural perceptions unique to the population.